The Cambridge, MA-based company priced its upsized public offering of 7.43 million shares at $18 per share.
The company had previously said that it would offer 6.25 million shares between the $15 and $17 per share range.
Seres Therapeutics' lead development candidate, SER-109, is an oral therapeutic for the prevention of Clostridium difficile infection which affects between 85,000 and 110,000 people in the U.S.
The drug candidatite is currently in Phase II trials.
The company also has five other drug candidates in its development pipeline at various trial stagesMCRB Price data by YCharts